Caudal-related homeobox 1 (CDX1), an intestinal-specific transcription factor, has been reported to have vital roles in gastric intestinal metaplasia (IM). Although IM is a high-risk factor for gastric cancer (GC), the specific role of CDX1 in GC is largely unknown. In this study, we investigated the expression of CDX1 and its functional roles in GC, and its upstream regulatory mechanisms at the microRNA (miRNA) level were further explored. We found that CDX1 is lost in GC when compared with adjacent IM tissues. Gain-offunction studies showed that CDX1 significantly inhibited GC cell growth by inducing cell cycle arrest and apoptosis. Interestingly, we identified and verified an onco-mir, miR-296-5p, as a direct upstream regulator of CDX1. miR-296-5p overexpression significantly promoted GC cell growth and attenuated the CDX1-induced anti-growth effects by recurring cell cycle distribution and apoptotic status, whereas knockdown of miR-296-5p decreased GC cell growth. Furthermore, we found that the extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation and the subsequent downstream changes in protein levels related to cell cycle and apoptosis partly account for the miR-296-5p-CDX1-induced GC growth promotion. In addition, the detection of miR-296-5p and expression of CDX1 in primary GC tissues and adjacent IM tissues revealed that miR-296-5p is inversely correlated with CDX1, further supporting our in vitro results. Our results showed an anti-growth effect of CDX1 and identified its miRNA regulatory mechanism in GC. The identification of this novel miR-296-5p-CDX1-ERK1/2 axis sheds new light on the understanding of the process from IM to GC and may provide therapeutic targets for the treatment of GC.
INTRODUCTION
Gastric cancer (GC) is the second highest cause of death from cancer globally, with low improvement of long-term survival in the past decade. 1 GC can be classified into two distinct histological groups: the diffuse type and the more frequent intestinal type, which develops through multiple well-defined stages, including intestinal metaplasia (IM). 2 Gastric IM is the most important precancerous lesion and risk factor of GC, resulting in an extremely high possibility of GC progression. 3, 4 Many transcription factors, such as caudal-related homeobox family genes, have been found to be deregulated and have a vital role in both IM and GC development. 5, 6 Caudal-related homeobox 1 (CDX1) is an intestinal-specific transcription factor belonging to the caudal-related homeobox family. Normally, CDX1 mediates the transformation of endoderm into the simple columnar epithelium, which characterizes the adult intestine. 7 Pathologically, CDX1 is believed to have a major role in the induction and maintenance of gastric IM. Studies have shown that transgenic mice overexpressing CDX1 in the stomach had extensive gastric IM, 8 which may be associated with the intestine-specific genes activated by CDX1. 9, 10 More recently, increasing evidence has shown that CDX1 has a role in tumor development. Studies have found that CDX1 downregulation is also associated with colorectal carcinogenesis. Loss of CDX1 expression has been confirmed in both colorectal cancer cell lines and clinical samples. [11] [12] [13] Many studies have shown that ectopic CDX1 expression inhibits the proliferation of colon cancer cells in vitro, [14] [15] [16] [17] suggesting CDX1 may act as an anti-proliferation factor in colorectal cancer. However, some researchers found that CDX1 is involved in tumorigenesis of intestinal epithelial cells, 18 which is contradictory to most studies. In addition, CDX1 gene expression was found to be decreased in several clinical GC samples compared with gastric IM tissues. 19, 20 To date, the function of CDX1 in GC and the mechanism underlying its downregulation remains largely unknown.
MicroRNAs (miRNAs) are important small non-coding RNAs, which inhibit translation or result in the degradation of target mRNA by binding to the 3 0 -untranslated region (3 0 -UTR). 21 Studies have identified many miRNAs that regulate various physiological processes, including the cell cycle, 22 apoptosis 23 and differentiation, 24 which are usually abnormally regulated in carcinogenesis. Recently, miRNAs have been found to promote or suppress tumor growth through regulating cell cycle-and apoptosis-related pathways. Particularly, miR-21 functions as an oncogene and accelerates tumor growth through the regulation of tumorsuppressor genes, including p53, transforming growth factorbeta and phosphatase and tensin homolog deleted on chromosome 10. [25] [26] [27] miR-199a-3p targeting of the oncogenes mammalian target of rapamycin, c-Met and PAK4 inhibited the proliferation of hepatocellular carcinoma cells. 28, 29 Among these miRNAs, miR-296 has been found to act as a cancer-promoting miRNA that induces multiple malignant phenotypes of tumors. [30] [31] [32] Specifically, glioma cells have an increased miR-296 level in endothelial cells, and this elevation significantly contributes to angiogenesis. 30 Moreover, in esophageal cancer, high expression of miR-296 might predict poor survival, and the downregulation of miR-296 might inhibit cancer cell growth. 31 Another study found that miR-296 is also enriched in both hepatocellular carcinoma and breast cancer, and this upregulation promotes cancer cell proliferation. 32 Our study showed that miR-296-5p, a mature form of miR-296, bioinformatically predicted to be a regulating miRNA of CDX1, is inversely correlated with CDX1 in GC cells. Based on this result and recent findings indicating the role of miR-296 in promoting the proliferation of various types of cancers, we hypothesized that miR-296-5p may partly account for the silence of CDX1 in GC and promotes GC growth through suppressing CDX1.
In this study, we investigated the tumor-suppressive function of CDX1 in GC and the mechanism of its downregulation directed by miR-296-5p. We validated that CDX1 was downregulated in GC tissues compared with adjacent IM tissues. We further found that CDX1 overexpression inhibited tumor growth in vitro. In addition, we identified miR-296-5p, which is upregulated in GC cell lines and tissues, as a regulating factor of CDX1 by targeting the 3 0 -UTR. We also found that the upregulation of miR-296-5p promoted GC growth, and the inhibition of miR-296-5p had opposite effects. Moreover, our study demonstrated that CDX1 was a functional target of miR-296-5p, and the miR-296-5p-CDX1 axis regulated GC cell growth through extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation. Finally, the reverse correlation of miR-296-5p and CDX1 expression was confirmed in primary GC tissues.
RESULTS

CDX1 was downregulated in GC tissues and inhibits GC cell growth
To examine the expression of CDX1 and its significance in GC development, we measured the expression of CDX1 in primary GC tissue arrays. Immunohistochemistry showed that normal gastric mucosa did not express CDX1, whereas IM tissues expressed significantly high levels of CDX1. Interestingly, CDX1 expression was found to be partly or completely lost in GC tissues as compared with adjacent IM tissues ( Figure 1a , Table 1 ). CDX1 was downregulated during the process of differentiation from IM to GC, indicating its potential role in suppressing tumor progression.
To investigate if CDX1 loss was involved in the increased growth of GC cells, a lentiviral vector encoding CDX1 (Lenti-CDX1) or empty vector (Lenti-Null) were transfected into AGS cells, which did not express a significant amount of CDX1 protein. After cell transfection and antibiotic screening for 6 weeks, extracts from Lenti-CDX1 and Lenti-Null AGS cells were compared by western blot (Figure 1b) . XTT assays showed that cell growth was significantly decreased by the induced expression of CDX1 in AGS cells as compared with Lenti-Null AGS cells (Figure 1c) . Cell cycle assays also showed that CDX1 overexpression in AGS cells increased the G0/G1 population and decreased the S and G2/M population as compared with Lenti-Null AGS cells (Figure 1d ). Moreover, apoptosis assays using Annexin V and propidium iodide staining found that the percentage of apoptotic cells in Lenti-CDX1 AGS cells increased compared with Lenti-Null AGS cells (Figure 1e ). Taken together, these results suggest that the downregulation of CDX1 is correlated with gastric carcinogenesis and that CDX1 might inhibit GC cells growth by blocking cell cycle progression and inducing apoptosis. miR-296-5p downregulated CDX1 expression by binding its 3 0 -UTR To investigate the mechanism of CDX1 downregulation, bioinformatic methods were used to identify the potential miRNAs regulating CDX1. Eleven miRNAs were computationally predicted using two independent miRNA databases: TargetScan (http:// www.targetscan.org) and MicroCosm (http://www.ebi.ac.uk/ enright-srv/microcosm/htdocs/targets/v5/). These included miR-637, miR-493, miR-765 and miR-296-5p. We were extremely interested in miR-296-5p because of its positive roles in tumor angiogenesis and proliferation. [30] [31] [32] We measured the miR-296-5p levels and the corresponding levels of CDX1 protein in various GC cell lines (Figures 2a and b) . Quantitative reverse-transcriptase PCR (qRT-PCR) and western blot results indicated that the endogenous level of CDX1 expression was inversely associated with that of miR-296-5p in six GC cell lines. CDX1 protein levels were relatively higher in the MKN28, SGC7901 and BGC823 cell lines, whereas the miR-296-5p levels were relatively lower in the other three cell lines. In contrast, relatively lower CDX1 expression and higher miR-296-5p expression of were validated in the AGS, GC9811 and MKN45 cell lines. Thus, the inverse expression levels of CDX1 and miR-296-5p in GC cell lines indicated that miR-296-5p may participate in the regulation of CDX1.
To determine whether miR-296-5p represses CDX1 expression by targeting its two binding sites (Figure 2c ), PCR products containing wild-type or mutant CDX1 3 0 -UTR binding sites were inserted into reporter vectors. Luciferase reporter assays showed that miR-296-5p caused a significant decrease in relative luciferase activity when the CDX1 plasmid containing wild-type 3 0 -UTR was present, but luciferase activity was not significantly changed in the 3 0 -UTR with mutant binding sites. This indicated that miR-296-5p may suppress CDX1 expression by simultaneously targeting the two binding sites of the CDX1 3 0 -UTR. Furthermore, qRT-PCR showed that overexpression or knockdown of miR-296-5p had no significant effect on CDX1 mRNA levels ( Figure 2e ). However, western blotting showed that overexpression of miR-296-5p significantly suppressed CDX1 expression in MKN28 cells and that silencing of miR-296-5p increased CDX1 expression in AGS cells (Figure 2f ), indicating that miR-296-5p regulates CDX1 at the post-transcriptional level. Taken together, these results suggest that miR-296-5p regulates CDX1 expression by directly targeting its 3 0 -UTR. miR-296-5p had positive effects on GC cell growth To investigate the functions of miR-296-5p on GC cell growth, two concentrations of miR-296-5p inhibitor or mimic were transfected into AGS cells and MKN28 cells, respectively, to conduct gain-offunction and loss-of-function experiments. miR-296-5p expression was confirmed by qRT-PCR after transfection (Figures 3a and b) . XTT assays showed that after miR-296-5p downregulation, AGS cell growth was significantly repressed as compared with negative control, whereas MKN28 cell growth was promoted by miR-296-5p upregulation. Further results indicated that the effects of the miR-296-5p inhibitor or mimic on GC cell growth were dose dependent ( Figure 3c ). In addition, apoptosis analysis demonstrated that miR-296-5p knockdown in AGS cells dose-dependently increased the number of apoptotic cells, and miR-296-5p overexpression decreased MKN28 apoptotic cells (Figure 3d ). We further conducted flow cytometry analysis of the cell cycle and found that repressing miR-296-5p expression led to a G0/G1 accumulation compared with the control cells, whereas restoring miR-296-5p expression in MKN28 cells led to the opposite results ( Figure 3e ). Accordant changes were observed in other GC cell lines including SGC7901, BGC823, GC9811 and MKN45 (Supplementary Figure S2) . The similar results were obtained in cells overexpressing CDX1, further demonstrating that miR-296-5p might be an important regulator of CDX1.
To further verify that miR-296-5p promotes the proliferation of GC cells through CDX1, we transfected AGS cells with a lentiviral vector encoding the CDS region of CDX1 with or without its 3 0 -UTR and measured CDX1 expression by western blot (Figure 4a ). After miR-296-5p was co-transfected into AGS cells, CDX1 expression was found to be significantly reduced in cells transfected with the miR-296-5p increases GC proliferation by suppressing CDX1 T Li et al wild-type 3 0 -UTR, whereas no difference was found in cells transfected with vector lacking the 3 0 -UTR sequence ( Figure 4b ). Furthermore, XTT assays demonstrated that restoration of miR-296-5p could significantly rescue the CDX1-induced promotion of GC cell growth (Figure 4c ). In addition, we found that miR-296-5p expression was able to abrogate the G0/G1 accumulation induced by CDX1 (Figure 4d ). Apoptosis assays also suggested that miR-296-5p upregulation was sufficient to decrease the percentage of CDX1-induced apoptotic cells (Figure 4d ). Taken together, these results suggest that CDX1 could be a functional target of miR-296-5p. miR-296-5p promoted GC growth through the miR-296-5p-CDX1-ERK axis To further investigate the mechanism underlying GC growth regulation by the miR-296-5p-CDX1 axis, we examined several key molecules in important dysregulated pathways in carcinogenesis. Western blot showed that ERK1/2 phosphorylation was significantly inhibited after knockdown of miR-296-5p in AGS cells, whereas AKT and nuclear factor-kB phosphorylation had no visible change, and no significant changes were found in ERK1/2, nuclear factor-kB and AKT expression (Figure 5a ). Thus, we deduced that miR-296-5p might promote GC growth through ERK1/2 phosphorylation. To investigate this hypothesis, we examined the levels of mitogen-activated protein kinase-related proteins and their phosphorylation in the gain-or loss-of-function of miR-296-5p and CDX1 model system. As is shown in Figure 5b , downregulation of miR-296-5p in AGS cells lead to a significant decrease in the phosphorylation of RAF-MEK-ERK pathway-related proteins without affecting their expression, which was also found in AGS cells transfected with the Lenti-CDX1 vector. However, miR-296-5p upregulation or CDX1 knockdown in MKN28 cells elicited similar Table 1 . Expression of CDX1 in normal, IM and GC tissues CDX1 expression level miR-296-5p increases GC proliferation by suppressing CDX1 T Li et al results, as the phosphorylation of RAF, MEK and ERK were decreased as compared with the negative control ( Figure 5c ). The changes likely induced by the regulation of miR-296-5p and CDX1 further indicated that miR-296-5p might affect GC cell growth through the downregulation of CDX1. More importantly, we found that restoring miR-296-5p could reverse the inhibition of ERK phosphorylation and downstream molecular changes induced by CDX1 with a 3 0 -UTR; however, this phenomenon was not observed in AGS cells transfected with vectors coding CDX1 without a 3 0 -UTR (Figure 5d ). To further verify whether ERK activation accounts for GC growth change induced by miR-296-5p-CDX1, we used PD98059, an inhibitor of ERK phosphorylation, for MKN28 cells transfected with miR-296-5p mimics or CDX1 lentiviral small interfering RNA (siRNA) vector. Western blot showed that PD98059 inhibited the phosphorylation of ERK1/2 without affecting CDX1 expression (Figure 6a ). XTT assay demonstrated that PD98059 abrogated the promotion of GC growth induced by miR-296-5p upregulation or CDX1 downregulation (Figure 6b ). In addition, fluorescenceactivated cell sorting assay found that the changes of cell cycle distribution caused by miR-296-5p mimics and CDX1 siRNA could be rescued by PD98059 (Figure 6c ). Apoptosis assay also showed PD98059 was able to increase the apoptotic cells percentage, which was decreased in cells transfected with miR-296-5p mimics or CDX1 siRNA (Figure 6d ). In addition, the similar results were observed in BGC823 cells (Supplementary Figure S3) . Collectively, these results suggested that miR-296-5p regulates ERK activity and promotes GC cell growth through the miR-296-5p-CDX1-ERK1/2 axis. miR-296-5p increases GC proliferation by suppressing CDX1 T Li et al miR-296-5p and CDX1 were inversely correlated in primary GC tissues To further validate the translational inhibition of CDX1 by miR-296-5p in primary GC tissues, 16 pairs of GC and adjacent IM specimens were examined for miR-296-5p and CDX1. As shown in figure 7a , western blot revealed CDX1 expression was partially or totally lost in 15 of 16 primary GC tissues, with an average value of 0.55, as compared, with adjacent IM tissues with an average value of 1.0 (Figure 7c ). qRT-PCR results showed that miR-296-5p was significantly upregulated in 15 matched pairs of GC tissues ( Figure 7b ) and was inversely correlated with CDX1 expression (Figure 7d) . Hence, these results show that CDX1 expression was progressively decreased in GC tissues, compared with precancerous lesions, and that this loss was related to the upregulation of miR-296-5p.
DISCUSSION
Gastric IM, the most common precancerous lesion in gastric carcinoma, is a high-risk factor of intestinal-type GC. 3, 4 Many transcription factors, including caudal-related homeobox genes, have been identified as being involved in the process of both IM and GC. 5, 6 Recently, studies showed that abnormal CDX1 expression is associated with colorectal cancer, and restoration of CDX1 may have negative effects on tumor proliferation. 11, 12, [14] [15] [16] [17] 19, 20, 33 In this study, we investigated the function of CDX1 in GC growth and preliminarily identified its regulatory mechanism.
CDX1 belongs to the caudal-related homeobox family that is important for intestinal development. It has a pivotal role in intestinal epithelial cell differentiation by directly regulating several intestinal-specific genes, such as A33 and cytokeratin 20.
9,10,34 CDX1 is believed to take part in inducing IM, 8, 35, 36 as miR-296-5p increases GC proliferation by suppressing CDX1 T Li et al researchers found that transgenic mice expressing CDX1 in gastric mucosa resulted in extensive gastric IM. Interestingly, CDX1 expression was found to be partly lost or diminished in gastric adenocarcinoma, 19, 20 indicating that the absence of CDX1 might be an advantage for the development of GC from gastric IM. In recent years, the expression and function of CDX1 in colorectal cancer has been investigated in several studies, and the results were somewhat contradictory. Most studies demonstrated that CDX1 is downregulated in colorectal cancer and acts as an antiproliferative gene. [11] [12] [13] Crissey et al. 17 found that Cdx1 may not behave as an oncogene in the normal intestinal epithelium. Further studies proved that CDX1 could inhibit proliferation by reducing cyclin D1 expression and b-catenin/Tcf transcription activity. [14] [15] [16] However, some other studies suggest CDX1 might be involved in the tumorigenesis of intestinal epithelial cells. 18 These findings suggest that the loss of CDX1 may be involved in sustaining proliferative signals. To date, few studies have investigated CDX1 function in GC and the mechanism underlying its miR-296-5p increases GC proliferation by suppressing CDX1 T Li et al downregulation. In our study, we found that CDX1 expression was partially or completely lost in GC as compared with adjacent IM tissues. Immunohistochemistry and western blot were used to support this conclusion in previously fixed GC tissues and fresh collected tissues, respectively. This result indicated the potential role of CDX1 in tumor suppression in GC. Our results further proved that ectopic CDX1 expression reduced the proliferative ability of GC cells. We found that restoring CDX1 in GC cells blocks cell cycle progression by arresting cells in G0/G1 and increasing apoptosis, leading to tumor growth suppression. Taken together, these results suggest that CDX1 expression is inhibited in gastric carcinoma, and this loss may be involved in the increased growth ability of GC cells. miRNAs are important small non-coding RNAs, usually expressed abnormally in carcinogenesis. Like transcription factors, miRNAs affect tumor progression through interacting with mRNAs of protein-coding genes. By pairing with the mRNAs and targeting their 3 0 -UTR, miRNAs induce oncogene and anti-oncogene mRNA degradation or translation disruption or a combination of the two. 21 Many miRNAs have been shown to affect the process of GC proliferation, 22 apoptosis, 37 metastasis 38,39 and multidrug resistance. 23 Typically, miRNAs exert their function by affecting multiple genes. Thus, one miRNA may have different function on interacting with different targets. 40 Among these miRNAs, miR-296 has been found to act as a cancer-promoting miRNA in several malignant phenotypes of tumors. [30] [31] [32] Wü rdinger et al.
30
found that glioma and angiogenic cells increases the level of miR-296 in endothelial cells, and this elevation significantly contributes to angiogenesis by directly targeting the hepatocyte growth factor-regulated tyrosine kinase substrate. In esophageal cancer, the high expression of miR-296 might predict poor survival, and the downregulation of miR-296 might inhibit cancer cell growth in vitro and in vivo through the regulation of cyclin D1 and p27. 31 Yoon et al. 32 also found that miR-296 is enriched in hepatocellular carcinoma and breast cancer and miR-296 upregulation promotes carcinogenesis by downregulating the P53-P21 waf1 pathway. These studies indicated that miR-296 may function as an oncogene and promote tumor proliferation in many types of cancers. However, miR-296 expression and function in GC remains unclear. In our study, we examined the role of miR-296-5p in CDX1 downregulation and GC growth. miR-296-5p was successfully predicted to target CDX1 by two independent databases. Our results showed that miR-296-5p is upregulated and inversely associated with CDX1 expression in both GC cell lines and primary GC tissues (Supplementary Figure S1) . The functional experiments with miR-296-5p indicated that miR-296-5p promoted GC cell growth by inducing G0/G1 arrest and resistance to apoptosis, which was inversely associated with CDX1 Figure 5 . miR-296-5p regulated ERK activity and promoted GC growth through the miR-296-5p-CDX1-ERK axis. (a) AKT, nuclear factor (NF)-kB and ERK1/2 expression and phosphorylation was examined by western blot in the AGS cells transfected with an miR-296-5p inhibitor or negative control at a concentration of 200 nM. (b) AGS cells were transfected with miR-296-5p inhibitors or Lenti-CDX1 and the corresponding negative control as indicated. CDX1, RAF1, MEK and ERK1/2 expression and phosphorylation were examined by western blot. (c) MKN28 cells were transfected with miR-296-5p mimics or CDX1 siRNA and the corresponding negative control. CDX1, RAF1, MEK and ERK1/2 expression and phosphorylation was examined by western blot. (d) AGS cells were transfected with Lenti-CDX1 containing wild-type 3 0 -UTR or lacking 3 0 -UTR, along with miR-296-5p or NC. CDX1, cyclin D1, Bcl2 and Bax expression and ERK1/2 phosphorylation were detected by western blot.
miR-296-5p increases GC proliferation by suppressing CDX1 T Li et al function, further indicating that miR-296-5p might promote tumor growth through inhibiting CDX1 expression. Using a luciferase reporter gene assay, we demonstrated thatmiR-296-5p directly targeted the two binding sites on the CDX1 mRNA 3 0 -UTR. Transfection of miR-296-5p mimics or inhibitors was also found to alter the CDX1 protein level without affecting its mRNA level. Based on our results, we deduced that CDX1 is a functional target of miR-296-5p. To further confirm this hypothesis, we cotransfected miR-296-5p and CDX1 and showed that the downregulation of CDX1 by miR-296-5p relies on the CDX1 3 0 -UTR. Most importantly, functional experiments revealed that restoration of miR-296-5p could rescue the growth inhibition, cell cycle distribution and apoptosis induced by CDX1 overexpression in GC. This provided direct evidence that miR-296-5p promotes GC cell growth by inhibiting CDX1 expression. In addition, it is worth noting that one study found that miR-296 expression was lower in several types of cancer, including GC; 41 however, this study lacked functional experiments in GC cells and relatively limited GC specimen capacity, which might be major limitations.
The mitogen-activated protein kinase pathway participates in a wide variety of cellular processes, such as proliferation, apoptosis, differentiation, transcription regulation and development. 42 Deregulation of the mitogen-activated protein kinase pathway is common in various cancers, including GC. The prototypical mitogen-activated protein kinase pathway is the ERK1/2 pathway, which is preferentially activated by mitogenic factors, differentiation stimuli and cytokines. 43 Activation of the ERK1/2 pathway was found to be both necessary and sufficient for the transcriptional induction of the cyclin D1 gene and then promotes G1 progression and tumor proliferation. 44, 45 ERK1/2 is also involved in tumor cell survival through the regulation of Bcl2/ Bax activation. 46, 47 In this study, based on the results that GC cell proliferation and apoptosis were affected by miR-296-5p and CDX1 expression, we studied if the ERK1/2 pathway participates in this process. Our results showed that miR-296-5p downregulation and CDX1 restoration in AGS cells caused similar changes, significantly decreasing phosphorylation of RAF-MEK-ERK. In addition, the levels of the RAF1, MEK and ERK phosphorylation increased after miR-296-5p upregulation or CDX1 knockdown in MKN28 cells. The same phenomenon that was induced by the opposite regulation of miR-296-5p and CDX1 suggest that miR-296-5p might activate the ERK1/2 pathway through inhibiting CDX1. Moreover, we found that CDX1 overexpression in AGS cells affected the expression of proteins downstream from ERK1/2, including cyclin D1 and Bcl2/Bax, which is supported by previous studies in colorectal cancer. 14, 15 Further results indicated that the inhibition of ERK1/2 induced by ectopic CDX1 expression could be rescued after co-transfection of miR-296-5p, whereas this phenomenon was not observed in the absence of the CDX1 3 0 -UTR containing miR-296-5p binding sites. These results showed that the effect of miR-296-5p on ERK1/2 pathway was CDX1 dependent. Most importantly, through growth assay after inhibiting ERK phosphorylation, we found that ERK activation was required for increase in GC growth induced by miR-296-5p-CDX1 manipulation. In conclusion, our findings suggest that miR-296-5p promotes ERK1/2 activation through targeting CDX1. Thus, the activation of ERK1/2 might contribute to GC growth promotion induced by the miR-296-5p-CDX1 axis. As discussed before, CDX1 reduces b-catenin/TCF activity and cyclin D1 expression in cancer cells, resulting in cell cycle blocking. Recent Figure 6 . ERK activation was required for increase in GC growth induced by miR-296-5p-CDX1 (a) MKN28 cells were transfected with miR-296-5p mimics at a final concentration of 100 nM or lentiviral vector coding CDX1 siRNA or negative control, in the absence or presence of PD98059 (50 mM). CDX1 expression and ERK1/2 phosphoralation were examined by western blot. b-Actin was used as an internal control. miR-296-5p increases GC proliferation by suppressing CDX1 T Li et al study demonstrates that Axin could inhibit the Raf1, MEK and ERK activation in fibroblast cells retaining wild-type but not mutant b-catenin gene, 48 which suggests that the effect of CDX1 on ERK signaling inhibition involves the Wnt/b-catenin pathway components. Future studies will be directed at whether in GC cells the change of b-catenin activity is responsible for the decrease in cyclin D1 induced by CDX1 restoration.
In summary, we found that CDX1 expression was significantly downregulated in GC tissues as compared with IM tissues and acted as a tumor suppressor in GC growth. More importantly, miR-296-5p overexpression in GC was responsible for CDX1 inhibition and facilitated growth by affecting the cell cycle and apoptosis. Our study further demonstrated that miR-296-5p promoted GC growth through inhibiting CDX1, and the inactivation of the ERK1/2 pathway induced by CDX1 could be reversed by miR-296-5p in GC cells. This miR-296-5p-ERK1/2 signaling axis may provide novel insights into the mechanisms of GC progression from IM and might be helpful for the treatment of GC.
MATERIALS AND METHODS
Tissues and cell lines
Paired samples of primary GC, adjacent normal tissues and IM tissues were obtained with informed consent from patients who had undergone GC surgery at Xijing Hospital, Xi'an, China. All the samples were shown to be correctly labeled clinically and pathologically (Supplementary Table S1 ). This study was approved by the Hospital's Protection of Human Subjects Committee. GES-1, AGS, SGC7901, GC9811, MKN45 and MKN28 cells were maintained in RPMI-1640 medium; BGC823 and HEK293T cells were cultured in Dulbecco's modified Eagle's medium (Thermo Scientifc miR-296-5p increases GC proliferation by suppressing CDX1 T Li et al HyClone, Beijing, China). All cells were incubated at 37 1C in a humidified atmosphere containing 5% CO 2 . PD98059 (Cell Signaling Technology, Beverly, MA, USA) were dissolved in dimethyl sulfoxide, and used at 50 mM.
Tissue microarrays GC tissue microarrays (no. ST781, ST1004 and ST806) were purchased from Alenabio (Xi'an, China). Thirty cases of gastric malignant tissues and their matched adjacent normal and IM tissues were included for further experiments and statistical analysis.
Immunohistochemistry
Immunohistochemistry was performed using an anti-CDX1 antibody (Sigma-Aldrich Inc., St Louis, MO, USA) for 1 h at 22 1, followed by counterstaining with hematoxylin. Expression levels were visualized and classified based on the percentage of positive cells and the intensity of staining. The percentage of positive cells was divided into four grades (percentage cores): o1% (0), 1-25% (1), 26-50% (2), 51-75% (3) and 475% (4). The intensity of staining was divided into four grades (intensity scores): negative (0), weak (1), moderate (2) and strong (3). The histological score was determined by the following formula: overall scores ¼ percentage score Â intensity score. An overall score of 0-12 was calculated and graded as negative ( À , score: 0), weak ( þ , score: 1-4), moderate ( þ þ , score: 5-8) or strong ( þ þ þ , score: 9-12).
Lentivirus infection and oligonucleotide transfection
The CDX1 overexpression and siRNA constructs were purchased from GeneChem (Shanghai, China). The constructs containing CDX1 CDS or siRNA sequence and 100 bases of the upstream and downstream regions flanking these sequences were inserted into the pGCSIL-GFP vector. Target cells (1 Â 10 5 ) were subcultured in 24-well plates and infected with 2 Â 10 7 lentivirus transducing units in the presence of 5 mg/ml polybrene. Empty lentiviral vector was used as the negative control. The miR-296-5p mimics or inhibitor and corresponding negative control were designed and synthesized by RiBoBio (Guangzhou, China). Target cells were transfected with miR-296-5p mimics or inhibitor and correlated negative control using DharmaFect Transfection reagent (Thermo-Fisher, Lafayette, CO, USA) according to the manufacturer's protocol. Cells were collected 48 h after transfection.
Western blot
Total proteins were prepared from fresh frozen tissue or cultured cell samples by complete cell lysis (Roche, Mannheim, Germany) with protease and phosphatase inhibitor. Denatured proteins (20-50 mg) were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and transferred to polyvinylidene difluoride membranes. The following primary antibodies were used: CDX1 (Sigma-Aldrich Inc.), ERK1/2 (Abcam, Cambridge, MA, USA), pERK1/2 (T202/Y204, Abcam), nuclear factor-kB-p105 (Bioworld, Nanjing, China), pNFkB-p105 (S907, Bioworld), AKT (Cell Signaling Technology), pAKT (Cell Signaling Technology), Raf1 (Abcam), pRaf1 (Abcam), MEK1 (Bioworld), pMEK1 (Bioworld), CyclinD1 (Bioworld), Bcl2 (Bioworld), Bax (ZSGB, Beijing, China) and b-actin (Sigma-Aldrich Inc.). The bands were scanned using ChemiDocXRS þ Imaging System (Bio-Rad, Hercules, CA, USA) and quantified using Quantity One v4.6.2 software (BioRad).
XTT assays XTT assays were conducted to determine the cell growth according to the manufacturer's instructions (Cell Proliferation Kit II (XTT), 11 465 015 001, Roche, Mannheim, Germany). Target cells (1000 per well) were seeded in 96-well plates, and the volume of culture medium was set to 100 ml. XTT (sodium 3-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate) labeling reagent (final concentration of 0.3 mg/ml) and electron-coupling reagent (PMS, N-methyl dibenzopyrazine methyl sulfate) were mixed, and 50 ml of the mixture was added to the wells. The cells were incubated with the reagents for 6 h. Varioskan Flash Multimode Reader (Thermo-Fisher) was used to read the absorbance at 466 nm with a reference wavelength at 650 nm.
Cell cycle and apoptosis assays
For cell cycle analysis, target cells were fixed in 75% ethanol and stained with propidium iodide supplemented with RNase A (Roche, Mannheim, Germany) for 30 min at 22 1C after antibiotic scanning for 48 h posttransfection as indicated. The Annexin V-FITC Apoptosis Detection Kit was used for apoptosis assays. Cells (1 Â 10 4 ) were stained according to the manufacturer's protocol and sorted using a fluorescence-activated cell sorting sorter (BD Biosciences, La Jolla, CA, USA), and the data were analyzed using the Modfit software (BD Biosciences).
RNA extraction and quantitative RT-PCR
Total RNA for cultured cells was extracted by TRizol reagent (Invitrogen, Carlsbad, CA, USA). The miRNA of fresh frozen tissues was extracted using a miRNeasy Mini Kit (Qiagen, Hilden, Germany). The RT and PCR primers for miR-296-5p and U6 were purchased from RiboBio (Guangzhou, China). The PCR primers for CDX1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were as follows: CDX1-forward 5 0 -TTACAGCCGTTACATCACAA TCC-3 0 , CDX1-reverse 5 0 -CTTGTTCACTTTGCGCTCCT-3 0 ; GAPDH-forward 5 0 -ATGTCGTGGAGTCTACTGGC-3 0 , GAPDH-reverse 5 0 -TGACCTTGCCCACAG CCTTG-3 0 . Reverse transcription PCR was performed using the PrimeScript RT reagent kit (TaKaRa, Dalian, China) following the manufacturer's instruction. Quantitative real-time PCR was performed using SYBR Premix Ex Taq II (TaKaRa) and measured in a LightCycler 480 system (Roche, Basel, Switzerland). Expression of U6 or GAPDH was used as the internal control. 2 À DDCT referred to the fold-change of the RNA expression of one sample when compared with the calibration sample.
Plasmid construction
The plasmid construction for the luciferase reporter gene assay was performed as previously described. 38 The wild-type 3 0 -UTR of CDX1 containing two putative binding sites for miR-296-5p was amplified using genomic DNA from HEK293T cells as a template. The correlated mutant constructs were created by mutating the seed regions of the miR-296-5p binding sites. Both wild-type and mutant 3 0 -UTRs were cloned downstream of the luciferase gene in the psiCHECK-2 luciferase vector. The constructs were verified by sequencing.
Luciferase reporter assays
For luciferase assays, HEK293T cells were transfected with appropriate plasmids in 24-well plates. Cells were harvested and lysed for luciferase assays 48 h after transfection. Luciferase assays were performed using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the manufacturer's protocol. Firefly luciferase activity normalized to Renilla luciferase was used as an internal control. The transfection experiments were performed in triplicate for each plasmid construct.
Statistical analysis SPSS software (version 12.0, SPSS Inc., Chicago, IL, USA) was used for statistical analyses. Continuous data were presented as the mean ± s.e.m. and were compared between two groups by Student's unpaired t-test. The linear correlation coefficient (Pearson's r) was calculated to determine the correlation between CDX1 and miR-296-5p expression in paired tissues. Po0.05 was considered to be statistically significant (*Po0.05, **Po0.01 and ***Po0.001).
